newsfilter
← Latest News
GlobeNewswire·

Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

- Company expects to resubmit New Drug Application (NDA) for oxylanthanum carbonate (OLC) assuming completion of successful inspection of third-party manufacturing vendor - FDA has assigned a facility inspection to